Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Buccal Drug Delivery System Market Size from 2025 to 2034?
The market size of the buccal drug delivery system has significantly expanded in the past few years. It is projected to increase from $3.55 billion in 2024 to $3.89 billion in 2025, showcasing a compound annual growth rate (CAGR) of 9.5%. This substantial growth in the previous period is attributed to drug delivery innovation at an early stage, adoption by the pharmaceutical industry, effectiveness demonstrated through clinical studies, strategic market penetration, and applications specific to certain diseases.
The buccal drug delivery system market is predicted to experience a significant boost in its size in the upcoming years. The market is projected to reach a value of $5.88 billion by 2029, expanding at a compound annual growth rate (CAGR) of 10.9%. Factors contributing to the growth during the forecast period include patient-oriented drug delivery, an increasing ageing population, the need for targeted treatments, and delivery of biologics and peptides, as well as regulatory support and approvals, and investments in research and development. Noteworthy trends for the forecast period encompass patient comfort and adherence, progression in drug formulations, the surge in chronic illnesses, care for pediatric and geriatric patients, and improved bioavailability.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Buccal Drug Delivery System Market?
The growth of the buccal drug delivery systems market is anticipated to be driven by the increasing incidence of chronic diseases. Chronic diseases, such as diabetes, cancer, heart disease, stroke, and arthritis, are conditions that last for over a year and, while they can be managed, they cannot be cured. These diseases require ongoing medical care and nutrition. The administration of mucosal and transmucosal drugs, necessary for many patients with chronic diseases like cancer and diabetes, is effectively and appropriately supported by buccal drug delivery systems. The World Health Organization, a specialized agency of the United Nations based in Switzerland, reported in September 2023 that of the 41 million deaths caused by non-communicable diseases (NCDs) or chronic diseases globally each year, 74% were due to chronic diseases. This included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the buccal drug delivery systems market’s growth is being fueled by the increasing incidence of chronic diseases.
Which Key Market Segments Comprise the Buccal Drug Delivery System Market and Drive Its Revenue Growth?
The buccal drug delivery systemmarket covered in this report is segmented –
1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays
2) By Application: Pain Management, Smoking Cessation, Angina Pectoris
3) By End-User: Hospitals, Ambulatory Centers, Other End-Users
Subsegments:
1) By Sublingual: Sublingual Tablets, Sublingual Films
2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges
3) By Oral Sprays: Spray Solutions, Spray Gels
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp
Which Areas Are Leading Regions in the Buccal Drug Delivery System Market Expansion Across the Globe?
North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theBuccal Drug Delivery System Market Direction?
Leading firms in the buccal drug delivery systems market are concentrating on the development of innovative solutions, including oral therapies for plaque psoriasis. This approach is aimed at maximizing patient benefits and augmenting the efficiency of drug delivery. Oral therapies for plaque psoriasis entail the oral administration of drugs to control and ease the signs of plaque psoriasis. This is a chronic autoimmune disorder typified by rapid skin cell proliferation leading to the formation of thick, crimson patches coated with scales. For example, Bristol Myers Squibb, a pharmaceutical firm based in the US, received FDA authorization for Sotyktu (deucravacitinib) in September 2022. This oral therapy is designed for adults suffering from moderate-to-severe plaque psoriasis. The FDA’s approval signals the inception of the first new oral treatment for this condition in nearly ten years. Its unique mechanism of action centers on selectively inhibiting tyrosine kinase 2 (TYK2).
View the full report here:
https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report
How Is the Buccal Drug Delivery System Market Conceptually Defined?
The buccal drug delivery system refers to the injection of the desired medicine through the buccal mucosal membrane lining of the mouth cavity. This method is effective for administering mucosal and transmucosal drugs. Mucosal drug delivery aims for site-specific drug release on the mucosa, whereas transmucosal permeation entails drug absorption across the mucosal barrier and into the systemic circulation.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8290
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model